APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gliclazide Sustained-release Tablet

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gliclazide Sustained-release Tablet Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchGliclazide Sustained-release Tablet Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Gliclazide Sustained-release Tablet Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gliclazide Sustained-release Tablet Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gliclazide Sustained-release Tablet Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Gliclazide Sustained-release Tablet Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Gliclazide Sustained-release Tablet market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gliclazide Sustained-release Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gliclazide Sustained-release Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gliclazide Sustained-release Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gliclazide Sustained-release Tablet market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gliclazide Sustained-release Tablet market include Yiling Pharmaceutical, Teva, Shijiazhuang SIYAO, Sanofi S.A., Mylan Pharmaceuticals, Lukang Jituan Saite Yaoye, Zydus Cadila Healthcare, Torrent Pharmaceuticals and Servier Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gliclazide Sustained-release Tablet market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gliclazide Sustained-release Tablet and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gliclazide Sustained-release Tablet sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gliclazide Sustained-release Tablet market size, projected growth trends, production technologies, key applications, and end-use industries.

Gliclazide Sustained-release Tablet Segment by Company

Yiling Pharmaceutical

Teva

Shijiazhuang SIYAO

Sanofi S.A.

Mylan Pharmaceuticals

Lukang Jituan Saite Yaoye

Zydus Cadila Healthcare

Torrent Pharmaceuticals

Servier Laboratories

Aurobindo Pharma

Accord Healthcare

Gliclazide Sustained-release Tablet Segment by Type

30mg

60mg

Other

Gliclazide Sustained-release Tablet Segment by Application

Hospital

Clinic

Other

Gliclazide Sustained-release Tablet Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gliclazide Sustained-release Tablet status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gliclazide Sustained-release Tablet market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gliclazide Sustained-release Tablet significant trends, drivers, influence factors in global and regions.

6. To analyze Gliclazide Sustained-release Tablet competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gliclazide Sustained-release Tablet market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gliclazide Sustained-release Tablet and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gliclazide Sustained-release Tablet.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gliclazide Sustained-release Tablet market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gliclazide Sustained-release Tablet industry.

Chapter 3: Detailed analysis of Gliclazide Sustained-release Tablet manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gliclazide Sustained-release Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gliclazide Sustained-release Tablet in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gliclazide Sustained-release Tablet Industry Trends Table 2. Gliclazide Sustained-release Tablet Industry Drivers Table 3. Gliclazide Sustained-release Tablet Industry Opportunities and Challenges Table 4. Gliclazide Sustained-release Tablet Industry Restraints Table 5. Global Gliclazide Sustained-release Tablet Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gliclazide Sustained-release Tablet Revenue Share by Company (2021-2026) Table 7. Global Gliclazide Sustained-release Tablet Sales Volume by Company (k units) & (2021-2026) Table 8. Global Gliclazide Sustained-release Tablet Sales Volume Share by Company (2021-2026) Table 9. Global Gliclazide Sustained-release Tablet Average Price (US$/unit) of Company (2021-2026) Table 10. Global Gliclazide Sustained-release Tablet Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gliclazide Sustained-release Tablet Key Company Manufacturing Base & Headquarters Table 12. Global Gliclazide Sustained-release Tablet Company, Product Type & Application Table 13. Global Gliclazide Sustained-release Tablet Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gliclazide Sustained-release Tablet by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 30mg Table 18. Significant Companies of 60mg Table 19. Significant Companies of Other Table 20. Global Gliclazide Sustained-release Tablet Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2021-2026) & (k units) Table 22. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2027-2032) & (k units) Table 23. Global Gliclazide Sustained-release Tablet Sales Volume Share by Type (2021-2026) Table 24. Global Gliclazide Sustained-release Tablet Sales Volume Share by Type (2027-2032) Table 25. Global Gliclazide Sustained-release Tablet Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gliclazide Sustained-release Tablet Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gliclazide Sustained-release Tablet Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gliclazide Sustained-release Tablet Sales Value Share by Type (2021-2026) Table 29. Global Gliclazide Sustained-release Tablet Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global Gliclazide Sustained-release Tablet Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2021-2026) & (k units) Table 35. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2027-2032) & (k units) Table 36. Global Gliclazide Sustained-release Tablet Sales Volume Share by Application (2021-2026) Table 37. Global Gliclazide Sustained-release Tablet Sales Volume Share by Application (2027-2032) Table 38. Global Gliclazide Sustained-release Tablet Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Gliclazide Sustained-release Tablet Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Gliclazide Sustained-release Tablet Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Gliclazide Sustained-release Tablet Sales Value Share by Application (2021-2026) Table 42. Global Gliclazide Sustained-release Tablet Sales Value Share by Application (2027-2032) Table 43. Global Gliclazide Sustained-release Tablet Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Gliclazide Sustained-release Tablet Sales by Region (2021-2026) & (k units) Table 45. Global Gliclazide Sustained-release Tablet Sales Market Share by Region (2021-2026) Table 46. Global Gliclazide Sustained-release Tablet Sales by Region (2027-2032) & (k units) Table 47. Global Gliclazide Sustained-release Tablet Sales Market Share by Region (2027-2032) Table 48. Global Gliclazide Sustained-release Tablet Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Gliclazide Sustained-release Tablet Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Gliclazide Sustained-release Tablet Sales Value Share by Region (2021-2026) Table 51. Global Gliclazide Sustained-release Tablet Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Gliclazide Sustained-release Tablet Sales Value Share by Region (2027-2032) Table 53. Global Gliclazide Sustained-release Tablet Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Gliclazide Sustained-release Tablet Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Gliclazide Sustained-release Tablet Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Gliclazide Sustained-release Tablet Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Gliclazide Sustained-release Tablet Sales by Country (2021-2026) & (k units) Table 58. Global Gliclazide Sustained-release Tablet Sales Market Share by Country (2021-2026) Table 59. Global Gliclazide Sustained-release Tablet Sales by Country (2027-2032) & (k units) Table 60. Global Gliclazide Sustained-release Tablet Sales Market Share by Country (2027-2032) Table 61. Global Gliclazide Sustained-release Tablet Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Gliclazide Sustained-release Tablet Sales Value Market Share by Country (2021-2026) Table 63. Global Gliclazide Sustained-release Tablet Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Gliclazide Sustained-release Tablet Sales Value Market Share by Country (2027-2032) Table 65. Yiling Pharmaceutical Company Information Table 66. Yiling Pharmaceutical Business Overview Table 67. Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product Portfolio Table 69. Yiling Pharmaceutical Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Teva Gliclazide Sustained-release Tablet Product Portfolio Table 74. Teva Recent Development Table 75. Shijiazhuang SIYAO Company Information Table 76. Shijiazhuang SIYAO Business Overview Table 77. Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product Portfolio Table 79. Shijiazhuang SIYAO Recent Development Table 80. Sanofi S.A. Company Information Table 81. Sanofi S.A. Business Overview Table 82. Sanofi S.A. Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Sanofi S.A. Gliclazide Sustained-release Tablet Product Portfolio Table 84. Sanofi S.A. Recent Development Table 85. Mylan Pharmaceuticals Company Information Table 86. Mylan Pharmaceuticals Business Overview Table 87. Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio Table 89. Mylan Pharmaceuticals Recent Development Table 90. Lukang Jituan Saite Yaoye Company Information Table 91. Lukang Jituan Saite Yaoye Business Overview Table 92. Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product Portfolio Table 94. Lukang Jituan Saite Yaoye Recent Development Table 95. Zydus Cadila Healthcare Company Information Table 96. Zydus Cadila Healthcare Business Overview Table 97. Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product Portfolio Table 99. Zydus Cadila Healthcare Recent Development Table 100. Torrent Pharmaceuticals Company Information Table 101. Torrent Pharmaceuticals Business Overview Table 102. Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio Table 104. Torrent Pharmaceuticals Recent Development Table 105. Servier Laboratories Company Information Table 106. Servier Laboratories Business Overview Table 107. Servier Laboratories Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Servier Laboratories Gliclazide Sustained-release Tablet Product Portfolio Table 109. Servier Laboratories Recent Development Table 110. Aurobindo Pharma Company Information Table 111. Aurobindo Pharma Business Overview Table 112. Aurobindo Pharma Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Aurobindo Pharma Gliclazide Sustained-release Tablet Product Portfolio Table 114. Aurobindo Pharma Recent Development Table 115. Accord Healthcare Company Information Table 116. Accord Healthcare Business Overview Table 117. Accord Healthcare Gliclazide Sustained-release Tablet Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Accord Healthcare Gliclazide Sustained-release Tablet Product Portfolio Table 119. Accord Healthcare Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Gliclazide Sustained-release Tablet Distributors List Table 123. Gliclazide Sustained-release Tablet Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Gliclazide Sustained-release Tablet Product Image Figure 2. Global Gliclazide Sustained-release Tablet Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gliclazide Sustained-release Tablet Sales (2021-2032) & (k units) Figure 5. Global Gliclazide Sustained-release Tablet Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Gliclazide Sustained-release Tablet Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 30mg Image Figure 10. 60mg Image Figure 11. Other Image Figure 12. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Gliclazide Sustained-release Tablet Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gliclazide Sustained-release Tablet Sales Volume Share by Type (2021-2032) Figure 15. Global Gliclazide Sustained-release Tablet Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gliclazide Sustained-release Tablet Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gliclazide Sustained-release Tablet Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Gliclazide Sustained-release Tablet Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Gliclazide Sustained-release Tablet Sales Volume Share by Application (2021-2032) Figure 24. Global Gliclazide Sustained-release Tablet Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Gliclazide Sustained-release Tablet Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Gliclazide Sustained-release Tablet Sales Value Share by Application (2021-2032) Figure 27. Global Gliclazide Sustained-release Tablet Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Gliclazide Sustained-release Tablet Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Gliclazide Sustained-release Tablet Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Gliclazide Sustained-release Tablet Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 32. North America Gliclazide Sustained-release Tablet Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Gliclazide Sustained-release Tablet Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Gliclazide Sustained-release Tablet Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 38. South America Gliclazide Sustained-release Tablet Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Gliclazide Sustained-release Tablet Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Gliclazide Sustained-release Tablet Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Gliclazide Sustained-release Tablet Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Gliclazide Sustained-release Tablet Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 30mg
  • 60mg
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Yiling Pharmaceutical
  • Teva
  • Shijiazhuang SIYAO
  • Sanofi S.A.
  • Mylan Pharmaceuticals
  • Lukang Jituan Saite Yaoye
  • Zydus Cadila Healthcare
  • Torrent Pharmaceuticals
  • Servier Laboratories
  • Aurobindo Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  4. 1.2.2 Global Gliclazide Sustained-release Tablet Sales Volume (2021-2032)
  5. 1.2.3 Global Gliclazide Sustained-release Tablet Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gliclazide Sustained-release Tablet Market Dynamics
  1. 2.1 Gliclazide Sustained-release Tablet Industry Trends
  2. 2.2 Gliclazide Sustained-release Tablet Industry Drivers
  3. 2.3 Gliclazide Sustained-release Tablet Industry Opportunities and Challenges
  4. 2.4 Gliclazide Sustained-release Tablet Industry Restraints
3 Gliclazide Sustained-release Tablet Market by Company
  1. 3.1 Global Gliclazide Sustained-release Tablet Company Revenue Ranking in 2025
  2. 3.2 Global Gliclazide Sustained-release Tablet Revenue by Company (2021-2026)
  3. 3.3 Global Gliclazide Sustained-release Tablet Sales Volume by Company (2021-2026)
  4. 3.4 Global Gliclazide Sustained-release Tablet Average Price by Company (2021-2026)
  5. 3.5 Global Gliclazide Sustained-release Tablet Company Ranking (2024-2026)
  6. 3.6 Global Gliclazide Sustained-release Tablet Company Manufacturing Base and Headquarters
  7. 3.7 Global Gliclazide Sustained-release Tablet Company Product Type and Application
  8. 3.8 Global Gliclazide Sustained-release Tablet Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gliclazide Sustained-release Tablet Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gliclazide Sustained-release Tablet Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gliclazide Sustained-release Tablet Market by Type
  1. 4.1 Gliclazide Sustained-release Tablet Type Introduction
  2. 4.1.1 30mg
  3. 4.1.2 60mg
  4. 4.1.3 Other
  5. 4.2 Global Gliclazide Sustained-release Tablet Sales Volume by Type
  6. 4.2.1 Global Gliclazide Sustained-release Tablet Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gliclazide Sustained-release Tablet Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gliclazide Sustained-release Tablet Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gliclazide Sustained-release Tablet Sales Value by Type
  10. 4.3.1 Global Gliclazide Sustained-release Tablet Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gliclazide Sustained-release Tablet Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gliclazide Sustained-release Tablet Sales Value Share by Type (2021-2032)
5 Gliclazide Sustained-release Tablet Market by Application
  1. 5.1 Gliclazide Sustained-release Tablet Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Gliclazide Sustained-release Tablet Sales Volume by Application
  6. 5.2.1 Global Gliclazide Sustained-release Tablet Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gliclazide Sustained-release Tablet Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Gliclazide Sustained-release Tablet Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Gliclazide Sustained-release Tablet Sales Value by Application
  10. 5.3.1 Global Gliclazide Sustained-release Tablet Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gliclazide Sustained-release Tablet Sales Value by Application (2021-2032)
  12. 5.3.3 Global Gliclazide Sustained-release Tablet Sales Value Share by Application (2021-2032)
6 Gliclazide Sustained-release Tablet Regional Sales and Value Analysis
  1. 6.1 Global Gliclazide Sustained-release Tablet Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gliclazide Sustained-release Tablet Sales by Region (2021-2032)
  3. 6.2.1 Global Gliclazide Sustained-release Tablet Sales by Region: 2021-2026
  4. 6.2.2 Global Gliclazide Sustained-release Tablet Sales by Region (2027-2032)
  5. 6.3 Global Gliclazide Sustained-release Tablet Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gliclazide Sustained-release Tablet Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gliclazide Sustained-release Tablet Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gliclazide Sustained-release Tablet Sales Value by Region (2027-2032)
  9. 6.5 Global Gliclazide Sustained-release Tablet Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  12. 6.6.2 North America Gliclazide Sustained-release Tablet Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  15. 6.7.2 Europe Gliclazide Sustained-release Tablet Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gliclazide Sustained-release Tablet Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  21. 6.9.2 South America Gliclazide Sustained-release Tablet Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gliclazide Sustained-release Tablet Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gliclazide Sustained-release Tablet Sales Value Share by Country, 2025 VS 2032
7 Gliclazide Sustained-release Tablet Country-level Sales and Value Analysis
  1. 7.1 Global Gliclazide Sustained-release Tablet Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gliclazide Sustained-release Tablet Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
  4. 7.3.1 Global Gliclazide Sustained-release Tablet Sales by Country (2021-2026)
  5. 7.3.2 Global Gliclazide Sustained-release Tablet Sales by Country (2027-2032)
  6. 7.4 Global Gliclazide Sustained-release Tablet Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gliclazide Sustained-release Tablet Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gliclazide Sustained-release Tablet Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gliclazide Sustained-release Tablet Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gliclazide Sustained-release Tablet Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gliclazide Sustained-release Tablet Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yiling Pharmaceutical
  2. 8.1.1 Yiling Pharmaceutical Company Information
  3. 8.1.2 Yiling Pharmaceutical Business Overview
  4. 8.1.3 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product Portfolio
  6. 8.1.5 Yiling Pharmaceutical Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Gliclazide Sustained-release Tablet Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Shijiazhuang SIYAO
  14. 8.3.1 Shijiazhuang SIYAO Company Information
  15. 8.3.2 Shijiazhuang SIYAO Business Overview
  16. 8.3.3 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product Portfolio
  18. 8.3.5 Shijiazhuang SIYAO Recent Developments
  19. 8.4 Sanofi S.A.
  20. 8.4.1 Sanofi S.A. Company Information
  21. 8.4.2 Sanofi S.A. Business Overview
  22. 8.4.3 Sanofi S.A. Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi S.A. Gliclazide Sustained-release Tablet Product Portfolio
  24. 8.4.5 Sanofi S.A. Recent Developments
  25. 8.5 Mylan Pharmaceuticals
  26. 8.5.1 Mylan Pharmaceuticals Company Information
  27. 8.5.2 Mylan Pharmaceuticals Business Overview
  28. 8.5.3 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio
  30. 8.5.5 Mylan Pharmaceuticals Recent Developments
  31. 8.6 Lukang Jituan Saite Yaoye
  32. 8.6.1 Lukang Jituan Saite Yaoye Company Information
  33. 8.6.2 Lukang Jituan Saite Yaoye Business Overview
  34. 8.6.3 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product Portfolio
  36. 8.6.5 Lukang Jituan Saite Yaoye Recent Developments
  37. 8.7 Zydus Cadila Healthcare
  38. 8.7.1 Zydus Cadila Healthcare Company Information
  39. 8.7.2 Zydus Cadila Healthcare Business Overview
  40. 8.7.3 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product Portfolio
  42. 8.7.5 Zydus Cadila Healthcare Recent Developments
  43. 8.8 Torrent Pharmaceuticals
  44. 8.8.1 Torrent Pharmaceuticals Company Information
  45. 8.8.2 Torrent Pharmaceuticals Business Overview
  46. 8.8.3 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio
  48. 8.8.5 Torrent Pharmaceuticals Recent Developments
  49. 8.9 Servier Laboratories
  50. 8.9.1 Servier Laboratories Company Information
  51. 8.9.2 Servier Laboratories Business Overview
  52. 8.9.3 Servier Laboratories Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Servier Laboratories Gliclazide Sustained-release Tablet Product Portfolio
  54. 8.9.5 Servier Laboratories Recent Developments
  55. 8.10 Aurobindo Pharma
  56. 8.10.1 Aurobindo Pharma Company Information
  57. 8.10.2 Aurobindo Pharma Business Overview
  58. 8.10.3 Aurobindo Pharma Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Aurobindo Pharma Gliclazide Sustained-release Tablet Product Portfolio
  60. 8.10.5 Aurobindo Pharma Recent Developments
  61. 8.11 Accord Healthcare
  62. 8.11.1 Accord Healthcare Company Information
  63. 8.11.2 Accord Healthcare Business Overview
  64. 8.11.3 Accord Healthcare Gliclazide Sustained-release Tablet Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Accord Healthcare Gliclazide Sustained-release Tablet Product Portfolio
  66. 8.11.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gliclazide Sustained-release Tablet Value Chain Analysis
  2. 9.1.1 Gliclazide Sustained-release Tablet Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gliclazide Sustained-release Tablet Sales Mode & Process
  6. 9.2 Gliclazide Sustained-release Tablet Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gliclazide Sustained-release Tablet Distributors
  9. 9.2.3 Gliclazide Sustained-release Tablet Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst